| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $1.66 | - | - |
| Q3'26 | $1.55 | $1.64 | +6.1% |
| Q2'26 | $1.57 | $1.39 | -11.5% |
| Q3'25 | $0.78 | $0.85 | +9.2% |
| Q2'25 | $2.21 | $2.87 | +29.7% |
| Q1'25 | $1.56 | $1.45 | -6.9% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $1.9B | - | - |
| Q3'26 | $1.7B | $1.7B | +0.1% |
| Q2'26 | $1.7B | $1.7B | +0.0% |
| Q3'25 | - | $1.4B | - |
| Q2'25 | - | $2.0B | - |
| Q1'25 | - | $1.7B | - |
Market Data
CLX is currently trading at $95.57, giving The Clorox Company a market cap of 11.71B and a P/E ratio of 15.5. Today's range spans $95.00–$96.00, with shares opening at $95.00 and moving down $0.44 (0.5%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 53/100.
Over the past year CLX has traded between $84.70 and $132.03 - the current price is +12.8% off the 52-week low and -27.6% from the high. 27 analysts cover the stock with a Hold consensus and a mean 12-month target of $105.29 (range $83.00–$163.00), implying upside of +10.2%.
The Clorox Company (CLX) is at $95.57 (in the lower half of its 52-week range in $84.70–$132.03), carrying a SELL signal (32/100) and neutral sentiment (53/100). The current P/E ratio stands at 15.5. The 11.71B market cap in Consumer Defensive means this name is well-covered by analysts who can accelerate the downside through rating cuts and target reductions - a feedback loop that smaller stocks with less coverage don't face to the same degree.
Analyst coverage for CLX becomes a double-edged factor in a SELL phase: at 11.71B in Consumer Defensive market cap, active coverage is high enough that downgrade risk is real and impactful. The 32/100 technical reading and neutral sentiment (53/100) at $95.57 (in the lower half of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $84.70–$132.03 range establishes where that repricing lands.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).